Affordable Access

Access to the full text

Effect of Dupilumab on Depression in Asthma with Eosinophilic Chronic Rhinosinusitis in the Japanese Population

Authors
  • Koya, Toshiyuki
  • Sakai, Natsumi
  • Sasaki, Takanobu
  • Shinbori, Kaori
  • Nagai, Asuka
  • Kimura, Yosuke
  • Toyama, Mio
  • Hayashi, Masachika
  • Saito, Akira
  • Nishiyama, Yuki
  • Hasegawa, Takashi
  • Muramatsu, Yoshiyuki
  • Muramatsu, Kumiko
  • Horii, Arata
  • Kikuchi, Toshiaki
Type
Published Article
Journal
International Archives of Allergy and Immunology
Publisher
S. Karger AG
Publication Date
Oct 15, 2021
Volume
183
Issue
3
Pages
289–297
Identifiers
DOI: 10.1159/000519296
PMID: 34657036
Source
Karger
Keywords
Disciplines
  • Clinical Allergy – Research Article
License
Green
External links

Abstract

Introduction: Psychological disorders, such as depression, are markedly prevalent in patients with airway diseases. In this study, we assessed the effect of treatment with dupilumab, an IL-4 receptor α chain antibody, on depressive symptoms in a cohort of patients with asthma with eosinophilic chronic rhinosinusitis (ECRS). Methods: The study participants, diagnosed with asthma and ECRS, were assessed for symptoms and quality of life (QOL) scores for asthma and ECRS and medications. The Patient Health Questionnaire-9 (PHQ-9) scores were used to evaluate the depressive state. The depressive symptoms were compared with asthma and ECRS symptoms both at the time of initiation and after 4 months of dupilumab treatment. Results: Ultimately, 31 patients were included in the study. Most patients demonstrated a depressive state that was correlated with the nasal symptom score. In the evaluation 4 months after dupilumab treatment, the PHQ-9 score was significantly reduced, and the decrease was remarkable in patients whose nasal symptom score was reduced by 50% or more. Additionally, the PHQ-9 scores in patients with improved nasal and asthma symptoms were significantly reduced. Discussion/Conclusion: Dupilumab may improve QOL in patients with bronchial asthma with ECRS by reducing depressive symptoms through the improvement of clinical symptoms.

Report this publication

Statistics

Seen <100 times